Literature DB >> 29353973

Prognostic evaluation of postoperative adjuvant therapy for operable cervical cancer: 10 years' experience of National Cancer Center in China.

Tong Shu1, Dan Zhao1, Bin Li1, Yating Wang1, Shuanghuan Liu1, Pingping Li1, Jing Zuo1, Ping Bai1, Rong Zhang1, Lingying Wu1.   

Abstract

OBJECTIVE: The aim of this study was to investigate the prognostic factors and to evaluate the impact of adjuvant therapy on clinical outcome for early-stage cervical cancer.
METHODS: The clinical-pathological data of all 1,335 patients with the International Federation of Gynecology and Obstetrics (FIGO) Ib-IIa cervical cancer treated with primary radical surgery at the Chinese National Cancer Center between May 2007 and Dec 2013 were retrospectively reviewed. The median follow-up was 70 months.
RESULTS: Of all the patients, 61.6% of the cases received adjuvant therapy, with 5-year disease-free survival (DFS) of 92.1% and 5-year overall survival (OS) of 95.0%. In multivariate analysis, differentiation of G3 (P<0.05), lymph node metastasis (LNM, P<0.05) and lymphovascular space invasion (LVSI, P<0.05) were independent predictors for OS, while LNM (P<0.05), deep stroma invasion (DSI, P<0.05) and LVSI (P<0.05) were independent factors for DFS. The samples were stratified by histologic type, and cervical squamous cell carcinoma (SCC) was found to share the same independent factors except for differentiation of OS. As to patients with cervical adenocarcinoma/adenosquamous carcinoma (AC/ASC), differentiation was the independent predictor of OS (P<0.05); and LVSI of DFS (P<0.05). Of 236 patients with high-risk factors, there was no significant difference in survival between concurrent chemoradiotherapy (CCRT, n=195), radiotherapy (RT, n=24), and chemotherapy (CT, n=17). Among the 190 patients with LNM who underwent CCRT, 124 cases showed improved DFS after sequential CT (P=0.118), with a recurrence rate decrease of 14%, though the difference was not statistically significant. Patients with single intermediate-risk factors like DSI or LVSI were found to partially benefit from adjuvant therapy, but the difference was not statistically significant.
CONCLUSIONS: LNM, LVSI, DSI and differentiation were found to be independent prognostic factors for operable cervical cancer. Aggressive postoperative adjuvant therapy based on single risk factors in Chinese National Cancer Center could benefit survival. CCRT+CT outperformed CCRT in high-risk patients. For patients with single non-high-risk factor, the role of adjuvant therapy needs to be further discussed.

Entities:  

Keywords:  Cervical neoplasm; DFS; OS; adjuvant therapy; prognostic factors

Year:  2017        PMID: 29353973      PMCID: PMC5775021          DOI: 10.21147/j.issn.1000-9604.2017.06.05

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  29 in total

1.  Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma.

Authors:  Seiji Mabuchi; Mika Okazawa; Koji Matsuo; Mahiru Kawano; Osamu Suzuki; Takashi Miyatake; Takayuki Enomoto; Shoji Kamiura; Kazuhiko Ogawa; Tadashi Kimura
Journal:  Gynecol Oncol       Date:  2012-06-21       Impact factor: 5.482

2.  Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.

Authors:  R J Zaino; S Ward; G Delgado; B Bundy; H Gore; G Fetter; P Ganjei; E Frauenhoffer
Journal:  Cancer       Date:  1992-04-01       Impact factor: 6.860

Review 3.  The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review.

Authors:  Munetaka Takekuma; Yuka Kasamatsu; Nobuhiro Kado; Shiho Kuji; Aki Tanaka; Nobutaka Takahashi; Masakazu Abe; Yasuyuki Hirashima
Journal:  J Obstet Gynaecol Res       Date:  2017-02-11       Impact factor: 1.730

4.  Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer.

Authors:  Yasuhiko Ebina; Nobuo Yaegashi; Hidetaka Katabuchi; Satoru Nagase; Yasuhiro Udagawa; Toru Hachisuga; Tsuyoshi Saito; Mikio Mikami; Yoichi Aoki; Hiroyuki Yoshikawa
Journal:  Int J Clin Oncol       Date:  2015-03-24       Impact factor: 3.402

5.  Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Marth; F Landoni; S Mahner; M McCormack; A Gonzalez-Martin; N Colombo
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

6.  Prognostic Parameters for Patients with Cervical Cancer FIGO Stages IA2-IIB: A Long-Term Follow-Up.

Authors:  Bogdan Obrzut; Andrzej Semczuk; Maciej Naróg; Marzanna Obrzut; Piotr Król
Journal:  Oncology       Date:  2017-05-03       Impact factor: 2.935

7.  Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer.

Authors:  A P Soisson; J T Soper; D L Clarke-Pearson; A Berchuck; G Montana; W T Creasman
Journal:  Gynecol Oncol       Date:  1990-06       Impact factor: 5.482

8.  Interdisciplinary S2k guideline on the diagnosis and treatment of cervical carcinoma.

Authors:  Matthias W Beckmann; Peter Mallmann
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-15       Impact factor: 4.553

9.  Node-positive cervical cancer: impact of pelvic irradiation and patterns of failure.

Authors:  R G Stock; A S Chen; J C Flickinger; S Kalnicki; J Seski
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-01-01       Impact factor: 7.038

10.  Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study.

Authors:  S Y Ryu; M H Kim; B H Nam; T S Lee; E S Song; C Y Park; J W Kim; Y B Kim; H S Ryu; S Y Park; K T Kim; C H Cho; C Lee; S M Kim; B G Kim; D S Bae; Y T Kim; J-H Nam
Journal:  Br J Cancer       Date:  2013-12-19       Impact factor: 7.640

View more
  7 in total

1.  Identification of differentially expressed genes in cervical cancer by bioinformatics analysis.

Authors:  Yanshan Ge; Chaoyang Zhang; Songshu Xiao; Lin Liang; Shan Liao; Yanqi Xiang; Ke Cao; Hongxiang Chen; Yanhong Zhou
Journal:  Oncol Lett       Date:  2018-06-12       Impact factor: 2.967

2.  Preoperative color Doppler ultrasonography predicts early recurrence in AFP-positive hepatocellular carcinoma.

Authors:  Miao Chen; Duo Wang; Yuan Zhao; Dan-Mei Lu; Hong-Xue Li; Jun-Jie Liu; Hang Li
Journal:  Oncol Lett       Date:  2019-09-09       Impact factor: 2.967

3.  Impact of different therapies on the survival of patients with stage I-IIA cervical cancer with intermediate risk factors.

Authors:  Jichan Nie; Qinjiao Wu; Anqi Yan; Zhiyong Wu
Journal:  Ann Transl Med       Date:  2021-01

4.  Postoperative Adjuvant Chemotherapy Improved the Prognosis in Locally Advanced Cervical Cancer Patients With Optimal Response to Neoadjuvant Chemotherapy.

Authors:  Xiaojie Feng; Hongmin Chen; Lei Li; Ling Gao; Li Wang; Xupeng Bai
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

5.  Comparison of Outcomes and Prognostic Factors Between Early-Stage Cervical Adenocarcinoma and Adenosquamous Carcinoma Patients After Radical Surgery and Postoperative Adjuvant Radiotherapy.

Authors:  Yuncan Zhou; Weiping Wang; Ke Hu; Fuquan Zhang
Journal:  Cancer Manag Res       Date:  2021-10-04       Impact factor: 3.989

6.  Cervical cancer prognosis and related risk factors for patients with cervical cancer: a long-term retrospective cohort study.

Authors:  Jina Li; Gaoming Liu; Jiayou Luo; Shipeng Yan; Ping Ye; Jie Wang; Miyang Luo
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

7.  Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery.

Authors:  Xiaojing Zhang; Zunfu Lv; Xiaoxian Xu; Zhuomin Yin; Hanmei Lou
Journal:  BMC Cancer       Date:  2020-07-16       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.